Natera, Inc. (NTRA)

107,31 +1,79 (+1,70 %) À la clôture : 04:00PM EDT

Natera, Inc.

13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
United States
650 980 9190
https://www.natera.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 3 282

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Matthew Rabinowitz Ph.D.	Co-Founder & Executive Chairman	768,38k	S.O.	1973
Mr. Steven Leonard Chapman	CEO & Director	1,59M	S.O.	1979
Mr. Michael B. Brophy M.B.A.	Chief Financial Officer	724,62k	S.O.	1980
Mr. Daniel Rabinowitz L.L.M.	Secretary & Chief Legal Officer	610,61k	S.O.	1969
Mr. John Fesko	President & Chief Business Officer	S.O.	S.O.	1979
Mr. Jonathan Sheena M.Eng.	Co-Founder & Director	293,91k	10,04M	1973
Ms. Olesya A. Anisimova CPA	Chief Accounting Officer	S.O.	S.O.	S.O.
Mr. Rishi Kacker	Chief Technology Officer	S.O.	S.O.	S.O.
Mr. Eric A. Evans	Chief Scientific Officer	S.O.	S.O.	S.O.
Mr. Jerry Diffley	Chief Compliance & Privacy Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Natera, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 4; Société : 8; Droits des actionnaires : 8; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.